Research and development expenses for the third quarter of 2025 increased to $9.6 million from $8.1 million for the prior year period. The increase was primarily due to a $0.9 million increase in ...
Discover how the ALYREF biomarker predicts bladder cancer aggressiveness and boosts immunotherapy response. Find out more ...
A new study has uncovered promising therapeutic strategies against one of the deadliest forms of prostate cancer.
AstraZeneca’s Alexion division has received FDA approval for Koselugo (selumetinib) to treat adults with NF1 who have symptomatic, inoperable plexiform neurofibromas. The decision is based on strong ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback